Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
← catalyst calendarNCT07222566 · readout in 923 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
1,410estimated
Sites
440
Countries
Argentina, Australia, Brazil +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-06 | actual | When the study began enrolling |
| Primary completion | 2029-02-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-08-26 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Metastatic Non Small Cell Lung Cancer
- Lung Cancer
Interventions
- Biological: PF-08634404
- Biological: Pembrolizumab
- Drug: Chemotherapy Regimen 1
- Drug: Chemotherapy Regimen 2
Primary outcomes
what the primary-completion date above is the date OFOverall Survival
measured Approximately 39 months
Progression Free Survival (PFS) assessed by blinded independent central review (BICR)
measured Approximately 32 months
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed